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Erratum
Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
Cynthia X. Ma, Shirong Cai, Shunqiang Li, Christine E. Ryan, Zhanfang Guo, W. Timothy Schaiff, Li Lin, Jeremy Hoog, Reece J. Goiffon, 
Aleix Prat, Rebecca L. Aft, Matthew J. Ellis, and Helen Piwnica-Worms
Original citation: J Clin Invest. 2012;122(4):1541–1552. doi:10.1172/JCI58765.
Citation for this erratum: J Clin Invest. 2012;122(7):2702. doi:10.1172/JCI64256.
The phrase “results in apoptosis” was inadvertently omitted from the fourth sentence of the abstract. The correct sentence appears 
below.
Previous studies have shown that inhibition of Chk1 in a p53-deficient background results in apoptosis in response to DNA damage.
The JCI regrets the error.
Corrigendum
Blood flow reprograms lymphatic vessels to blood vessels 
Chiu-Yu Chen, Cara Bertozzi, Zhiying Zou, Lijun Yuan, John S. Lee, MinMin Lu, Stan J. Stachelek, Sathish Srinivasan, Lili Guo, 
Andres Vicente, Patricia Mericko, Robert J. Levy, Taija Makinen, Guillermo Oliver, and Mark L. Kahn
Original citation: J Clin Invest. 2012;122(6):2006–2017. doi:10.1172/JCI57513.
Citation for this corrigendum: J Clin Invest. 2012;122(7):2702. doi:10.1172/JCI65314.
During the preparation of this manuscript, Andres Vicente’s name was spelled incorrectly in the author list. The correct author list is 
above.
The authors regret the error.
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